5′UTR sequence of highly expressed mRNA and its application

By optimizing the mRNA 5'UTR sequence, the problems of low translation efficiency and poor stability in the prior art were solved, and the effect of efficient expression of the target protein was achieved. The optimized sequence design improved the stability and translation efficiency of mRNA.

CN117778389BActive Publication Date: 2024-11-12SHENZHEN NEOCURNA BIOTECHNOLOGY CORP +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311788522.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-22
Publication Date
2024-11-12
Estimated Expiration
2043-12-22

AI Technical Summary

Technical Problem

The 5'UTR sequence design of existing mRNAs has problems affecting translation efficiency, especially in terms of exogenous protein expression and stability, and is sensitive to cell type and modified nucleotides, making it difficult to achieve efficient expression.

Method used

Design an optimized mRNA 5'UTR sequence with the general formula AUUCCCCG(N1)x(N2)U(N3)CUC(N4)pC(N5)yUGUCCCGCAGUCGGCGU CCAGCGCUCU(N6)qU(N7)zGUUCGUGU(N8)dUGUGUCGUUGCAG(N9 )eGC(N10)hUU(N11)(N12)f improves mRNA expression efficiency by optimizing the sequence structure.

Benefits of technology

By optimizing the 5'UTR sequence, the expression efficiency and stability of mRNA are significantly improved, and the protein of interest can be expressed efficiently in different cell types, reducing the sensitivity to modified nucleotides, close to or better than Moderna's 5'UTR- mRNA expression efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to a 5'UTR of mRNA, whose sequence composition is shown in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:14. The present invention also provides a highly expressed mRNA, wherein the 5'UTR of the mRNA has the composition of the above 5'UTR. The present invention optimizes and transforms the 5'UTR sequence of a suitable mRNA to obtain a 5'UTR sequence capable of increasing the expression amount of the mRNA, and the 5'UTR can be used to improve the expression efficiency of the mRNA encoding the target protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a 5'UTR sequence of mRNA obtained by optimizing and transforming the 5'UTR sequence of mRNA and its application. Background Art

[0002] As early as the 1960s, people began to use RNA to transfect cells, but it was not until 1990 that it was discovered that target proteins could be translated into mice by intramuscular injection of mRNA. However, after a long period of theoretical and practical accumulation, it was not until recent years that mRNA-based treatment methods began to make significant progress in various disease areas. Tumor vaccines based on mRNA technology and mRNA vaccines for preventing viral infections have shown encouraging prospects in clinical trials. So strictly speaking, although mRNA technology has been discovered for a long time, it is still a very new and cutting-edge treatment technology and direction for humans.

[0003] When expressing heterologous proteins, the stability of mRNA and the efficiency of foreign protein expression are improved through mRNA sequence design, inducing the body to produce more neutralizing antibodies. mRNA sequence design mainly includes: codon optimization, 5'UTR selection, and 3'UTR selection. Among them, the 5' untranslated region (5'UTR) plays an important role in gene expression regulation. It not only regulates gene expression at the translation level, but also participates in the regulation of eukaryotic gene transcription, post-transcriptional processing, mature RNA transport and other levels. The 5' untranslated region (5'UTR) of mRNA refers to the region of mature mRNA located upstream of the coding region (CDS) that is not translated into protein. It contains important regulatory elements, including the internal ribosome entry site (IRES), 5'UTR secondary structure, G-quadruplexes (G4), 5' cap structure, upstream open reading frame (uORF), Kozak sequence, upstream start codon AUG (upstream AUG, uAUG) and 5'UTR introns (5UIs). The regulation of gene expression by 5'UTR involves multiple levels and plays an important role in maintaining the stability of mRNA, nuclear transport, RNA splicing and processing, and cell proliferation.

[0004] In 1988, Kozak published an article in Molecular and Celluar Biology titled Leader length and secondary structure modulate mRNA function under conditions of stress. In COS cells, he found that the length of 5'UTR affects protein translation efficiency. Among the annotated vertebrate mRNA sequences, 75% of the mRNA 5'UTR lengths range from 20-100bp, 25% of the mRNA 5'UTR lengths range from 100-300bp, and it is very rare for the mRNA 5'UTR length to reach 1000bp. At that time, the relationship between 5'UTR length and translation efficiency was not known. Kozak found that the translation efficiency of mRNA carrying SV40 5'UTR with secondary structure was very sensitive to osmotic pressure after transfection into cells. In 1994, Kozak published an article in J Mol Biol titled "Features in the 5'non-coding sequences of rabbit alpha and beta-globin mRNAs that affect translational efficiency". Using the rabbit reticulocyte in vitro translation system, he first discovered that the 5'UTR region of alpha-globin mRNAs and beta-globin mRNAs affects their translation efficiency. beta-globin mRNAs have very high translation efficiency, and the translation efficiency is not reduced by the replacement of 5'UTR sequence bases, indicating that there is no special structural motif in the 5'UTR sequence of beta-globin mRNAs. However, if the base is replaced (introducing a GC-rich sequence) to form a secondary structure close to the Cap, the translation efficiency will be reduced. The efficient translation of beta-globin mRNAs requires a 5'UTR sequence of appropriate length. Shortening the 5'UTR sequence of beta-globin mRNA will reduce the translation efficiency. The researchers also found that the translation efficiency of the beUa-globin 5'UTR sequence was stronger than that of the alpha-globin 5'UTR sequence in the in vitro translation system. This may be due to the lack of secondary structure near the 5' end in the beta-globin 5'UTR sequence, while the secondary structure exists in the alpha-globin 5'UTR sequence.

[0005] Studies have found that the effect of UTR on mRNA translation efficiency is also highly dependent on the secondary structure. Inserting modified nucleotides into RNA molecules may affect the secondary structure of RNA, which may cause UTR to lose its function of mediating protein translation. Therefore, in order to overcome these limitations, a relatively short UTR can better achieve the preset purpose. It is very necessary to design the shortest UTR sequence, which can not only be free from the influence of cell type differences, but also minimize the impact on translation efficiency when inserting modified nucleotides.

[0006] In 2019, Carsten Rudolph published an article in Tissue Engineering: Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5'-UTRs, which aims to combine the shortest 5'UTR sequence and modified nucleotides to improve the translation efficiency of exogenous mRNA.

[0007] Existing research results show that the composition and construction of 5'UTR have a significant impact on the expression of mRNA, and are complex and diverse. Therefore, sequence optimization of 5'UTR will significantly improve the efficiency of mRNA expression and enable efficient expression of the target protein. Summary of the invention

[0008] Based on this, the purpose of the present invention is to provide an optimized 5'UTR sequence of highly expressed mRNA and its application.

[0009] The technical solutions for achieving the above-mentioned purpose include the following.

[0010] A 5'UTR of an mRNA, wherein the 5'UTR sequence has the following general formula:

[0011] AUUCCCCG(N1)x(N2)U(N3)CUC(N4)pC(N5)yUGUCCCGCAGUCGGCGU CCAGCGGCUCUGCU(N6)qU(N7)zGUUCGUGU(N8)dUGUGUCGUUGCAG(N9)eGC(N10)hUU(N11)(N12)f

[0012] Where N1=C, x=0 or 1,

[0013] N2=A or U or C or G,

[0014] N3=A or U or C or G,

[0015] N4=UA,p=0 or 1,

[0016] N5=G,y=0 or 1,

[0017] N6=A,q=0 or 1,

[0018] N7=UCGA, z=0 or 1,

[0019] N8=G,d=0 or 1,

[0020] N9=C,e=0 or 1,

[0021] N10=C or G, h=0 or 1,

[0022] N11=A or U or C or G,

[0023] N12 = any length of base combination, but cannot end with AU.

[0024] In some embodiments, N1=C, x=1,

[0025] N2=C,

[0026] N3=C.

[0027] In some of the embodiments, the composition of the 5'UTR is as shown in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:14.

[0028] In some of the embodiments, the sequence of the 5'UTR consists of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:10, or SEQ ID NO:11.

[0029] In some of the embodiments, the sequence composition of the 5'UTR is shown in SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:10.

[0030] In some embodiments, the sequence composition of the 5'UTR is shown in SEQ ID NO:10.

[0031] The second aspect of the present invention is to provide the use of any of the above 5'UTRs in increasing the expression level of mRNA for a target protein.

[0032] The target protein is the protein expressed corresponding to the CDS region of the mRNA.

[0033] The third aspect of the present invention is to provide a highly expressed mRNA, wherein the 5'UTR of the mRNA is any of the 5'UTRs described above.

[0034] In some of these embodiments, the BamHI composition of the mRNA is GGAUCC.

[0035] In some embodiments, the composition of the 3'UTR of the mRNA is as shown in SEQ ID NO:16.

[0036] In some embodiments, the composition of the polyA of the mRNA is as shown in SEQ ID NO:17.

[0037] The technicians of the present invention have found in their research that by optimizing and modifying the 5'UTR sequence of a suitable mRNA, a 5'UTR sequence capable of increasing the mRNA expression level is obtained, and the 5'UTR can be used to increase the expression efficiency of the mRNA encoding the target protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is a schematic diagram of the protein expression results of each eGFPdegron-mRNA in the examples. DETAILED DESCRIPTION

[0039] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0040] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions, such as the fourth edition of Molecular Cloning: A Laboratory Manual edited by Green and Sambrook, published in 2013, or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.

[0041] The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.

[0042] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.

[0043] The present invention is further described in detail below with reference to specific embodiments.

[0044] The present invention confirms whether the sequence after 5'UTR optimization of mRNA has better target protein expression efficiency through transfection and sample detection at a cytological level, and screens out the sequence with excellent expression efficiency by comparing with the control group, thereby achieving the purpose of mRNA sequence optimization.

[0045] The present invention synthesizes mRNA with optimized 5'UTR sequence in vitro, detects the expression efficiency of target protein at the in vitro cytological level on mRNA with eGFP degron as the reporter gene, and screens out 5UTR-mRNA with expression efficiency better than or close to that of Moderna. It is clear to those skilled in the art that, through the corresponding examples of the present invention, when the sequence expressed in the CDS region (Coding Sequence-referring to the protein coding region) is replaced with other proteins or antigens, the sequence optimized by the 5'UTR of the present invention can also efficiently express the protein.

[0046] In some embodiments, the optimization of the 5'UTR comprises the following steps:

[0047] S100: Cell plating

[0048] S200: Cell transfection

[0049] S300: Cell detection and result analysis

[0050] The present invention mainly screens out mRNA with optimized 5'UTR sequence through in vitro cell expression experiments, and the expression efficiency is better than or close to that of Moderna's 5UTR-mRNA.

[0051] 5'UTR general formula:

[0052] AUUCCCCG(N1)x(N2)U(N3)CUC(N4)pC(N5)yUGUCCCGCAGUCGGCGU CCAGCGGCUCUGCU(N6)qU(N7)zGUUCGUGU(N8)dUGUGUCGUUGCAG(N9)eGC(N10)hUU(N11)(N12)f

[0053] N1=C,x=0 / 1,

[0054] N2=A / U / C / G,

[0055] N3=A / U / C / G,

[0056] N4=UA,p=0 / 1,

[0057] N5=G,y=0 / 1,

[0058] N6=A,q=0 / 1,

[0059] N7=UCGA,z=0 / 1,

[0060] N8=G,d=0 / 1,

[0061] N9=C,e=0 / 1,

[0062] N10=C / G,h=0 / 1

[0063] N11=A / U / C / G,

[0064] N12 = any length of base combination, but cannot end with AU. The " / " in the above text means optional.

[0065] Example 1

[0066] In this example, a total of 13 eGFPdegron-mRNAs (mRNAs with GFP fluorescent protein fused to C-degron at the end) were subjected to 5'UTR sequence optimization (see Table 1), of which the first mRNA was the control group of Moderna's 5UTR-mRNA (abbreviated as pNC-eGFPdegron5-5UTR-M in this example). The second to fourteenth mRNAs were experimental groups with different 5'UTR sequence optimizations. In addition, this example also set up a blank control group without adding any nucleic acid. Each group of mRNAs had 3 parallels.

[0067] Table 1 eGFP-degron-5'UTR sequence optimization mRNA sequence information

[0068]

[0069]

[0070] BamHI:GGAUCC

[0071] CDS: SEQ ID NO: 15

[0072] AUGGUGAGCAAGGGCGAGGAGCUGUUCACAGGCGUGGUGCCUAUCCUGGUGGAGCUGGAUGGCGACGUGAACGGCCACAAGUUCAGCGUGAGCGGCGAGGGCGAGGGAGACGCCACAUACGGCAAGCUGACACUGAAGUUCAUCUGCACCACCGGCAAGCUGCCUGUGCCCUGGCCUACACUGGUGACAACACUGACCUACGGCGUGCAGUGCUUCAGCCGGUACCCUGACCACAUGAAGCAGCACGACUUCUUCAAGAGCGCCAUGCCCGAGGGCUACGUGCAGGAGCGGACCAUCUUCUUCAAGGACGACGGCAACUACAAGACACGGGCCGAGGUGAAGUUCGAGGGCGACACACUGGUGAACCGGAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGGCCACAAGCUGGAGUACAACUACAACAGCCACAACGUGUACAUCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCGGCACAACAUCGAGGACGGCAGCGUGCAGCUGGCCGACCACUACCAGCAGAACACACCUAUCGGCGACGGCCCUGUGCUGCUGCCUGACAACCACUACCUGAGCACACAGAGCGCCCUGAGCAAGGACCCUAACGAGAAGAGAGACCACAUGGUGCUGCUGGAGUUCGUGACAGCCGCCGGCAUCACACUGGGCAUGGACGAGCUGUACAAGAGAAGCAGAGACAUCAGCCACGGCUUCCCUCCUGCUGUGGCCGCCCAGGACGACGGCACACUGCCUAUGAGCUGCGCCCAGGAGAGCGGCAUGGACAGACACCCUGCCGCCUGCGCCAGCGCCCGGAUCAACGUGUGAUGA。

[0073] 3'UTR:SEQ ID NO:16

[0074] GAGCUCCUGGUACUGCAUGCACGCAAUGCUAGCUGCCCCUUUCCCGUCCUGGGUACCCCGAGUCUCCCCGACCUCGGGUCCCAGGUAUGCUCCCACCUCCACCUGCCCCACUCACCUCUGCUAGUUCCAGACACCUCCCAAGCACGC AGCAAUGCAGCUCAAAACGCUUAGCCUAGCCACACCCCCACGGGAAACAGCAGUGAUUAACCUUUAGCAAUAAACGAAAGUUUAACUAAGCUAUACUAACCCCAGGGUUGGUCAAUUUCGUGCCAGCCACACCCUGGAGCUAGCCUCGAG.

[0075] polyA: SEQ ID NO: 17

[0076] AAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.

[0077] S100: Cell plating

[0078] S101: Cell digestion

[0079] Take out HEK293T cells (other cell lines can also be used) from the incubator, and perform cell digestion after observing the normal state of cells under an inverted microscope. First, pour the cell culture supernatant into the waste bottle, and add 6mL PBS pH7.4 Basic (1X) to rinse the cell culture surface, then pour the PBS pH7.4 Basic (1X) used to rinse the cells into the waste bottle, and use a pipette to add 1.5mL 0.25% Trypsin-EDTA digestion solution to moisten the cell culture surface, and then use a pipette to discard the digestion solution. Place the cells in a carbon dioxide incubator at 37°C and 5.0% CO2, incubate for 1 minute, add 10mL DMEM complete medium to infiltrate the cell culture surface, and then terminate the digestion. Use a pipette to blow the cells into a single cell suspension and transfer them to a new 15mL centrifuge tube.

[0080] S102: Cell counting

[0081] Pipette 10 μL of cell suspension into a 1.5 mL EP tube, add 10 μL of trypan blue dye, mix thoroughly and then pipette 10 μL of the mixture into the counting plate. Let it stand for 1 minute and count using a counter.

[0082] S103 cell seed plate

[0083] Take out the six-well plate, add 1*10^6 cells to each well, 4 of which are blank control wells for two people, and add DMEM complete medium to each well to 2mL. After shaking the cells in the plate horizontally up and down, place the culture plate in a carbon dioxide incubator at 37℃ and 5.0% CO2 for 24 hours.

[0084] S200: Cell transfection

[0085] S201: Cell medium replacement

[0086] After the cells were taken out for observation and no abnormalities were found and the cell confluence was within the range of 80% to 95%, the culture supernatant of the cells to be transfected was replaced with 1 mL of Opti-MEM serum-free medium.

[0087] S202: Transfection

[0088] For each mRNA sample, prepare two 1.5mL EP tubes A / B containing 100ul Opti-MEM serum-free culture medium, add 3μg of mRNA to be transferred to tube A, and add 3μL messenger max transfection reagent to tube B. Mix gently and let stand for 5 minutes, then mix the solutions in tubes A and B together, mix gently and incubate at room temperature for 20 minutes, then add all the transfection solution drops to the corresponding marked cell wells, shake the culture plate horizontally up and down and left and right for 15s, then put the culture plate in a carbon dioxide incubator at 37℃ and 5.0% CO2 for half an hour, then take it out and add 800μL DMEM complete culture medium, then put it in a carbon dioxide incubator at 37℃ and 5.0% CO2 for 15h.

[0089] S300: Cell detection and result analysis

[0090] S301: Cell collection

[0091] After observing that the cells are normal, remove the cell culture supernatant, then add 1mL PBS pH7.4 Basic (1X) and resuspend the cells with a pipette, and transfer the cells to a labeled 1.5mL EP tube. Centrifuge the cells at 4℃, 350RCF for 3 minutes, remove the supernatant, add 1mL PBS pH7.4 Basic (1X) to resuspend the cells, centrifuge the cells at 4℃, 350RCF for 3 minutes, and remove the supernatant. Resuspend the cells in 900μL PBS pH7.4 Basic (1X) per well, transfer to a flow tube, and place in an ice box to run the flow.

[0092] S302: Streaming parameter settings

[0093] 30,000 events were collected at low flow rate for analysis. The flow voltage settings are shown in Table 2 below:

[0094] Table 2

[0095]

[0096] S303: Flow cytometry result analysis:

[0097] The flow cytometry results were analyzed using Flowjo-V10. The results are shown in the attached Figure 1 .

[0098] Figure 1 Moderna in the above represents SEQ ID NO:1, NO.29 represents SEQ ID NO:2, NO.30 represents SEQ ID NO:3, NO.31 represents SEQ ID NO:4, NO.46 represents SEQ ID NO:5, NO.47 represents SEQ ID NO:6, NO.48 represents SEQ ID NO:7, NO.49 represents SEQ ID NO:8, NO.50 represents SEQ ID NO:9, NO.51 represents SEQ ID NO:10, NO.52 represents SEQ ID NO:11, NO.53 represents SEQ ID NO:12, NO.54 represents SEQ ID NO:13, and NO.55 represents SEQ ID NO:14.

[0099] Depend on Figure 1 It can be seen that the mRNA corresponding to the 5'UTR of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:14 has good protein expression in HEK293T cells. The protein expression of the mRNA corresponding to the 5'UTR of SEQ ID NO:9 and SEQ ID NO:12 is lower than that of Moderna's 5UTR-mRNA.

[0100] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A 5'UTR of an mRNA, characterized in that The 5'UTR sequence composition is shown in SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:

14.

2. The 5'UTR according to claim 1, characterized in that Said SEQ ID NO:

10.

3. The 5'UTR according to claim 2, characterized in that The sequence composition of the 5'UTR is shown in SEQ ID NO:

11.

4. Use of the 5'UTR according to any one of claims 1 to 3 in increasing the expression level of a target protein by mRNA.

5. A highly expressed mRNA, characterized in that The 5'UTR of the mRNA is the 5'UTR according to any one of claims 1 to 3.

6. The mRNA according to claim 5, characterized in that The composition of BamHI of the mRNA is GGAUCC.

7. The mRNA according to claim 5, characterized in that The composition of the 3'UTR of the mRNA is shown in SEQ ID NO:

16.

8. The mRNA according to any one of claims 5 to 7, characterized in that The composition of the polyA of the mRNA is shown in SEQ ID NO:17.